Aprotinin does not prolong the Sonoclot aprotinin-insensitive activated clotting time

Yue Dong, Gregory A. Nuttall, William C. Oliver, Shvetank Agarwal, Mark H. Ereth

Research output: Contribution to journalArticle

Abstract

Study Objective: To determine whether a new Sonoclot-based, aprotinin-insensitive activated clotting time (aiACT) assay yields stable results over a broad range of aprotinin concentrations. Design: Prospective trial conducted on in vitro blood samples. Setting: Tertiary-care teaching medical center. Participants: 19 healthy adult volunteers. Interventions: Whole blood samples were collected from volunteers. Heparin (2 U/mL) and escalating concentrations of aprotinin of 160 to 500 kallikrein inhibitory units (KIU)/mL were added in vitro. Measurements and Main Results: Celite ACT, kaolin ACT, and aiACT assays were completed. The aiACT showed stable activated clotting time (ACT) results on heparinized, noncitrated blood with added aprotinin (P = nonsignificant). In contrast, celite ACT and kaolin ACT were greatly prolonged when aprotinin was added to heparinized, noncitrated, and citrated blood (P < 0.05). The aiACT had consistent results at all aprotinin concentrations (P = nonsignificant). Conclusions: Aprotinin (160, 320, and 500 KIU/mL) significantly prolongs the ACT value with celite and kaolin activators but not with the aprotinin-insensitive activator.

Original languageEnglish (US)
Pages (from-to)424-428
Number of pages5
JournalJournal of Clinical Anesthesia
Volume19
Issue number6
DOIs
StatePublished - Sep 1 2007

Fingerprint

Aprotinin
Diatomaceous Earth
Kaolin
Kallikreins
Tertiary Healthcare
Heparin
Volunteers
Healthy Volunteers
Teaching

Keywords

  • Activated clotting time
  • Anticoagulation
  • Aprotinin
  • Aprotinin-insensitive ACT
  • Cardiopulmonary bypass
  • Sonoclot analysis

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Aprotinin does not prolong the Sonoclot aprotinin-insensitive activated clotting time. / Dong, Yue; Nuttall, Gregory A.; Oliver, William C.; Agarwal, Shvetank; Ereth, Mark H.

In: Journal of Clinical Anesthesia, Vol. 19, No. 6, 01.09.2007, p. 424-428.

Research output: Contribution to journalArticle

Dong, Yue ; Nuttall, Gregory A. ; Oliver, William C. ; Agarwal, Shvetank ; Ereth, Mark H. / Aprotinin does not prolong the Sonoclot aprotinin-insensitive activated clotting time. In: Journal of Clinical Anesthesia. 2007 ; Vol. 19, No. 6. pp. 424-428.
@article{6943018e342145739abbf95f1ff6bc61,
title = "Aprotinin does not prolong the Sonoclot aprotinin-insensitive activated clotting time",
abstract = "Study Objective: To determine whether a new Sonoclot-based, aprotinin-insensitive activated clotting time (aiACT) assay yields stable results over a broad range of aprotinin concentrations. Design: Prospective trial conducted on in vitro blood samples. Setting: Tertiary-care teaching medical center. Participants: 19 healthy adult volunteers. Interventions: Whole blood samples were collected from volunteers. Heparin (2 U/mL) and escalating concentrations of aprotinin of 160 to 500 kallikrein inhibitory units (KIU)/mL were added in vitro. Measurements and Main Results: Celite ACT, kaolin ACT, and aiACT assays were completed. The aiACT showed stable activated clotting time (ACT) results on heparinized, noncitrated blood with added aprotinin (P = nonsignificant). In contrast, celite ACT and kaolin ACT were greatly prolonged when aprotinin was added to heparinized, noncitrated, and citrated blood (P < 0.05). The aiACT had consistent results at all aprotinin concentrations (P = nonsignificant). Conclusions: Aprotinin (160, 320, and 500 KIU/mL) significantly prolongs the ACT value with celite and kaolin activators but not with the aprotinin-insensitive activator.",
keywords = "Activated clotting time, Anticoagulation, Aprotinin, Aprotinin-insensitive ACT, Cardiopulmonary bypass, Sonoclot analysis",
author = "Yue Dong and Nuttall, {Gregory A.} and Oliver, {William C.} and Shvetank Agarwal and Ereth, {Mark H.}",
year = "2007",
month = "9",
day = "1",
doi = "10.1016/j.jclinane.2007.03.003",
language = "English (US)",
volume = "19",
pages = "424--428",
journal = "Journal of Clinical Anesthesia",
issn = "0952-8180",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Aprotinin does not prolong the Sonoclot aprotinin-insensitive activated clotting time

AU - Dong, Yue

AU - Nuttall, Gregory A.

AU - Oliver, William C.

AU - Agarwal, Shvetank

AU - Ereth, Mark H.

PY - 2007/9/1

Y1 - 2007/9/1

N2 - Study Objective: To determine whether a new Sonoclot-based, aprotinin-insensitive activated clotting time (aiACT) assay yields stable results over a broad range of aprotinin concentrations. Design: Prospective trial conducted on in vitro blood samples. Setting: Tertiary-care teaching medical center. Participants: 19 healthy adult volunteers. Interventions: Whole blood samples were collected from volunteers. Heparin (2 U/mL) and escalating concentrations of aprotinin of 160 to 500 kallikrein inhibitory units (KIU)/mL were added in vitro. Measurements and Main Results: Celite ACT, kaolin ACT, and aiACT assays were completed. The aiACT showed stable activated clotting time (ACT) results on heparinized, noncitrated blood with added aprotinin (P = nonsignificant). In contrast, celite ACT and kaolin ACT were greatly prolonged when aprotinin was added to heparinized, noncitrated, and citrated blood (P < 0.05). The aiACT had consistent results at all aprotinin concentrations (P = nonsignificant). Conclusions: Aprotinin (160, 320, and 500 KIU/mL) significantly prolongs the ACT value with celite and kaolin activators but not with the aprotinin-insensitive activator.

AB - Study Objective: To determine whether a new Sonoclot-based, aprotinin-insensitive activated clotting time (aiACT) assay yields stable results over a broad range of aprotinin concentrations. Design: Prospective trial conducted on in vitro blood samples. Setting: Tertiary-care teaching medical center. Participants: 19 healthy adult volunteers. Interventions: Whole blood samples were collected from volunteers. Heparin (2 U/mL) and escalating concentrations of aprotinin of 160 to 500 kallikrein inhibitory units (KIU)/mL were added in vitro. Measurements and Main Results: Celite ACT, kaolin ACT, and aiACT assays were completed. The aiACT showed stable activated clotting time (ACT) results on heparinized, noncitrated blood with added aprotinin (P = nonsignificant). In contrast, celite ACT and kaolin ACT were greatly prolonged when aprotinin was added to heparinized, noncitrated, and citrated blood (P < 0.05). The aiACT had consistent results at all aprotinin concentrations (P = nonsignificant). Conclusions: Aprotinin (160, 320, and 500 KIU/mL) significantly prolongs the ACT value with celite and kaolin activators but not with the aprotinin-insensitive activator.

KW - Activated clotting time

KW - Anticoagulation

KW - Aprotinin

KW - Aprotinin-insensitive ACT

KW - Cardiopulmonary bypass

KW - Sonoclot analysis

UR - http://www.scopus.com/inward/record.url?scp=35448940947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35448940947&partnerID=8YFLogxK

U2 - 10.1016/j.jclinane.2007.03.003

DO - 10.1016/j.jclinane.2007.03.003

M3 - Article

C2 - 17967670

AN - SCOPUS:35448940947

VL - 19

SP - 424

EP - 428

JO - Journal of Clinical Anesthesia

JF - Journal of Clinical Anesthesia

SN - 0952-8180

IS - 6

ER -